DNA damage activates the G 2 cell cycle checkpoint to allow time for DNA repair before mitotic entry. The mechanism involves inhibition of the enzymatic activity for polo-like kinase 1 (Plk1), rendering Cdc25C with a basal phosphatase activity that is insufficient for converting Cdc2 to the fully active G 2 /M transition kinase. We found that cell cycle arrest at the G 2 /M boundary after ionizing radiation (IR) of breast carcinoma cells may involve repression of the gene for Plk1, PLK, mediated by the tumor-suppressor protein BRCA1. The p53-defective MT-1 cell line had an apparent accumulation of G 2 /M phase cells 12 h after irradiation. This response was preceded by a transient downregulation of PLK mRNA expression with a barely detectable level 6 h after exposure to IR but recovered after 12 h. A significantly lower fraction of irradiated BRCA1 À/À HCC1937 cells arrested in the G 2 / M phase after 12 h, and the transient response of PLK mRNA was also considerably impaired. After reconstitution of wild-type BRCA1 in the HCC1937 cells however, downregulation of PLK mRNA as well as Plk1 protein expression after IR was restored. Moreover, the suppression of PLK mRNA expression 6 h after irradiation was completely abolished by the specific CHEK1 kinase inhibitor UCN-01, further indicating that the effector mechanism of DNA damage on PLK signals through BRCA1 and its downstream CHEK1. Our observations provide new information about the diversity of regulatory mechanisms governed by BRCA1 in DNA damage checkpoint control. Oncogene (2003) 22, 8952-8955. doi:10.1038/sj.onc.1207000
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The effector mechanism of ionizing radiation (IR) in cancer therapy involves a temporary cell cycle delay at the G 2 /M boundary until DNA is repaired or cell death succeeds. In the orderly dividing cell, the transition from the G 2 phase to mitosis is inhibited through phosphorylations of the Cdc2 kinase of the Cdc2/cyclin B complex. Upon mitotic entry, these inhibitory phosphorylations are removed by the Cdc25C phosphatase. The activation of Cdc25C requires positive regulatory phosphorylation, accomplished by polo-like kinase 1 (Plk1) (Roshak et al., 2000) . DNA damage, activating G 2 checkpoint ATM (for 'ataxia telangiectasia mutated') kinase signaling (Bakkenist and Kastan, 2003) communicated through the downstream CHEK1 and CHEK2 kinases (Matsuoka et al., 1998; Yarden et al., 2002) , leads to inhibition of Plk1 activity (Smits et al., 2000; van Vugt et al., 2001) and, consequently, disruption of Cdc25C interaction with Cdc2 (Sanchez et al., 1997; Matsuoka et al., 1998; Lopez-Girona et al., 1999) .
Polo-like kinases are evolutionary conserved enzymes that are involved at several stages throughout mitotic progression (Nigg, 2001) . Most of the evidence implicating polo-like kinase in the activation of Cdc25C has evolved from work on Xenopus meiotic maturation (Kumagai and Dunphy, 1996) . Still, recent data support a regulatory role of the mammalian Plk1 at the cell cycle G 2 checkpoint (Smits et al., 2000; van Vugt et al., 2001) , although the finding that Cdc25c À/À mice did not display any obvious abnormalities in cellular response to DNA damage nor ability to activate Cdc2a (Chen et al., 2001) may argue against an essential function of Cdc25C in mammalian G 2 /M transition. The human Plk1 was identified on basis of its high expression levels in rapidly proliferating cells (Holtrich et al., 1994) . More recent data have suggested that elevated Plk1 expression in the primary tumor is associated with an unfavorable clinical outcome (Knecht et al., 1999; Kneisel et al., 2002) , and experimental silencing of Plk1 has been shown to inhibit proliferative capacity of tumor cells (Spa¨nkuch-Schmitt et al., 2002; Elez et al., 2003) . Efficient tumor cell cycle arrest at the G 2 /M boundary following IR exposure requires intact function of the tumor-suppressor protein BRCA1 (Scully and Livingston, 2000) , and here we report that the mechanism may involve repression of PLK gene expression.
Breast carcinoma cell lines were irradiated with a single dose of 8.0 Gy, representing a therapeutic option in radiation treatment of advanced cancer disease. Cell lines with defective p53 checkpoint mechanism were selected for analysis of specific G 2 phase events. The MT-1 cell line (Engebraaten and Fodstad, 1999) displayed complete absence of wild-type (wt) TP53-specific characteristics, such as radiation-induced mRNA expression of CDKN1A and MDM2 (data not shown) as well as cell cycle arrest at the G 1 /S boundary, but had instead an apparent accumulation of G 2 / M phase cells (B70% of the total cell counts) already 12 h after the radiation exposure (Figure 1 ). This response was preceded by a transient downregulation of PLK mRNA expression, with a barely detectable level 6 h after cellular exposure to the DNA-damaging treatment but almost recovered after 12 h (Figure 2) . A significantly lower fraction (B40% of the total cell counts) of irradiated BRCA1 À/À HCC1937 cells (Tomlinson et al., 1998) , in which TP53 is mutated (Tomlinson et al., 1998) and G 2 checkpoint signaling via the CHEK1 kinase is abrogated (Yarden et al., 2002) , were arrested in the G 2 /M phase after 12 h (Figure 1 ). In these cells, the response of the PLK mRNA to IR was also considerably impaired, with essentially a slight repression of the expression level after 6 h only ( Figure 2 ).
The HCC1937 cell line is hemizygous with respect to the BRCA1 disease-mutated allele 5382insC, and synthesizes a truncated BRCA1 protein that lacks parts of the extreme C-terminal BRCT repeats (Tomlinson et al., 1998; Scully et al., 1999) , which directly interact with transcriptional corepressors (Deng and Brodie, 2000) . Consistently, in the derivative HCC1937/ BRCA1wt cell line, containing retrovirally expressed wt BRCA1 (Scully et al., 1999) , the response of transient downregulation of PLK mRNA to IR was completely restored (Figure 2 ), as was essentially also the cell cycle G 2 /M phase arrest 12 h after IR exposure (B55% G 2 / M phase cells counted) (Figure 1 ). Although the parental HCC1937 cells also showed radiation-induced accumulation in G 2 /M phase, the kinetics was much slower than in the MT-1 cells (Figure 3 ). In irradiated HCC1937/ BRCA1wt cells, the more immediate G 2 /M phase accumulation was closely similar to that of the MT-1 cells, but, interestingly, the delayed G 2 /M phase arrest of the parental BRCA1 À/À HCC1937 cell line was also preserved after reversal of the nonfunctional BRCA1 phenotype (Figure 3 ). Residual characteristics of the parental HCC1937 cells in the HCC1937/BRCA1wt cells were also reported by the investigators who established the derivative cell line (Scully et al., 1999) . Though, the HCC1937/BRCA1wt cell line has shown valid for a variety of phenotypic properties directly related to an intact BRCA1 function (Scully et al., 1999; Ganesan et al., 2002) .
Whether Plk1 protein expression might correspond with the DNA damage-induced repression of PLK mRNA in a BRCA1-dependent manner was assayed by comparing the HCC1937/BRCA1wt and HCC1937 cell lines 12 h after IR exposure. As seen from Figure 4 , downregulation of the Plk1 protein level was observed in the cell line with intact BRCA1 constitution only and seemed to be directly correlated to the mRNA response.
PLK has been shown to be among several genes, encoding mitotic regulators, of which the mRNA expression levels are downregulated following activation of the G 2 cell cycle checkpoint (Crawford and Piwnica-Worms, 2001 ). The mechanism of PLK mRNA Figure 1 Effect of IR on cell cycle profiles in breast carcinoma cell lines with intact or defective BRCA1 constitution. The MT-1 cells (Engebraaten and Fodstad, 1999) and the HCC1937 cells (Tomlinson et al., 1998 ; obtained from the American Type Culture Collection), as well as the HCC1937/BRCA1wt cells, representing the HCC1937 parental cell line containing retrovirally expressed wt BRCA1 (Scully et al., 1999) , were analyzed. The efficiency of plasmid uptake and resulting full-length BRCA1 protein expression in the HCC1937/BRCA1wt cell line, kindly provided by Dr David M Livingston (Dana Farber Cancer Institute, Boston, MA, USA), have been validated in the reference report (Scully et al., 1999) . Moreover, we assayed emission of green fluorescence, encoded by the retroviral vector, before the infected cell line was used in experiments. All cell lines were routinely grown in RPMI 1640 medium supplemented with 10% fetal bovine serum and 2.0 mm glutamine. At 24 h before start of the experiments, this medium was replaced by medium containing 5% serum and the glutamine, and this experimental medium was again changed at time 0, when the cells were subjected to irradiation from a 60 Co source. The delivery of 8.0 Gy of IR to the treated cells ( þ ) was done in room temperature at a rate of approximately 1.0 Gy/min, whereas the unirradiated control cells (À) simultaneously were placed in room temperature to obtain exactly comparable conditions. The cells were further incubated for 12 h before the resulting cell cycle profiles were determined by flow cytometry analysis, according to the following procedure: The cells were harvested by trypsinization and resuspended in ice-cold PBS. After centrifugation, the cell pellets were fixed and stored in 100% methanol at À201C. The cells were subsequently stained with Hoechst 33258 in PBS and measured for their DNA content in a FACStar þ laser flow cytometer with excitation at 488 nm. On the histograms displayed, the peaks labeled 2N and 4N represent cells with DNA contents characteristic for the G 1 and G 2 /M phases of the cell cycle, respectively Figure 2 Different responses of mRNAs for PLK and CCNB1 after IR exposure in breast carcinoma cell lines with intact or defective BRCA1 constitution. In addition to the cell lines assayed in Figure 1 , an HCC1937 derivative cell line stably infected with a retroviral vector carrying a green fluorescent protein (GFP) but no BRCA1 allele (the HCC1937/GFP cells; Scully et al., 1999) was analyzed. Similarly to the HCC1937/BRCA1wt cell line, emission of green fluorescence by this control infected cell line, also kindly provided by Dr David M Livingston, was assayed before use in experiments. The four tumor cell lines were cultured and subsequently treated ( þ ) with 8.0 Gy of IR or left untreated (À), as described in the legend to Figure 1 . Following this, the cells were incubated for the indicated time periods before total RNA was extracted and analyzed by standard Northern blotting technique. The human cDNA clones for PLK and CCNB1 were obtained from RZPD Deutsches Ressourcenzentrum fu¨r Genomforschung GmbH (Berlin, Germany). The Northern blot membrane was also hybridized to an oligonucleotide probe complementary to nucleotides 287-305 of human 18S rRNA, used as RNA loading control downregulation after IR exposure may comprise a decrease in mRNA stability, as has been suggested for other G 2 phase genes (Datta et al., 1992; Maity et al., 1995) , or transcriptional repression possibly mediated by a repressor element in the PLK promoter (Uchiumi et al., 1997) . We have screened a variety of irradiated cell lines on a high-density cDNA array to identify candidate radiation-responsive genes (Stokke et al., in preparation). Among cDNAs encoding cell cycle genes on the array were the cDNAs for CCNB1, CCNA2, CDC25C, and PLK considered directly G 2 phaserelated, and among these PLK and CCNB1 seemed to be consistently regulated by IR. Expression of cyclin B1 has been reported to decrease upon ectopic introduction of BRCA1 in cell lines with intact as well as defective p53 checkpoint mechanism (MacLachlan et al., 2000) . In agreement with this finding, as seen from Figure 2 , the level of CCNB1 mRNA seemed to be somewhat higher in the HCC1937 cells compared with the MT-1 cells, and the higher expression level was significantly reduced following reconstitution of intact BRCA1 function in the HCC1937/BRCA1wt cell line. Furthermore, some additional repression of CCNB1 mRNA was found in both the MT-1 and HCC1937/BRCA1wt cells 6 h after IR exposure (Figure 2) .
The DNA damage-induced ATM kinase signals its downstream activity via BRCA1 (Cortez et al., 1999) and the CHEK1 and CHEK2 kinases (Sanchez et al., 1997; Matsuoka et al., 1998) , leading to arrest in the G 2 phase of the cell cycle until DNA repair is complete. It was recently suggested that BRCA1 directly mediates the ATM activity onto CHEK1 (Yarden et al., 2002) . Hence, to strengthen a possible association between BRCA1 and PLK, expression of PLK mRNA after IR exposure was analyzed in the presence of the selective CHEK1 inhibitor UCN-01 (100 nm). In both the MT-1 and HCC1937/BRCA1wt cell lines, the suppression of PLK mRNA expression 6 h after IR exposure was completely abolished by UCN-01 ( Figure 5 ). We also observed that these cell lines no longer arrested at the G 2 /M checkpoint after IR in the presence of UCN-01 (data not shown), precisely as reported previously for HCC1937 cells reconstituted with wt BRCA1 (Yarden et al., 2002) .
In clinical radiation therapy, a minimal tumor cell delay in the cell cycle G 2 phase is desirable to limit the probability of double-strand DNA break repair before mitotic entry. Our results, indicating that the inhibition of Plk1 activity in DNA damage checkpoint control (Smits et al., 2000; van Vugt et al., 2001 ) principally may comprise a gene repression mechanism, may suggest a therapeutic benefit of PLK gene replacement therapy in tumor cell radiosensitization. Pharmacological targeting of the signaling pathways involved may also be a therapeutic strategy, and the specific inhibitor UCN-01 is among several novel drugs, designed to target the G 2 phase of the cell cycle, which are currently in pipeline for testing in early-phase clinical trials. Figure 3 The pattern of redistribution of cell cycle phases after IR exposure is a function of the cellular BRCA1 constitution in cell lines with defective p53 checkpoint mechanism. The four cell lines were cultured and subsequently treated ( þ ) with 8.0 Gy of IR or left untreated (À). Following this, the cells were incubated for the indicated time periods before cellular DNA contents were determined by flow cytometry analysis, as described in the legend to Figure 1 . The distribution of cell cycle phases is displayed as columns representing the phase-specific percentages of each total cell counts: shaded, G 1 phase cells; white, S phase cells; black, G 2 / M phase cells Figure 4 Repression of Plk1 expression after IR exposure is dependent on intact BRCA1 constitution. The HCC1937/ BRCA1wt and parental HCC1937 cell lines were cultured and treated ( þ ) with 8.0 Gy of IR or left untreated (À), as previously described, and subsequently incubated for 12 h and harvested. The cell pellets were lysed by the addition of ice-cold lysis buffer (50 mm Tris-HCl, pH 7.4, 150 mm NaCl, 1% NP-40, 0.25% sodium deoxycholate, 1 mm EGTA, 1 mm PMSF, 1 mm Na 3 VO 4 , 1 mm NaF, 1 mg/ml each of aprotinin, leupeptin, and pepstatin) and rocking for 30 min at 41C. The lysates were cleared by centrifugation. Aliquots of 100 mg of total protein were separated on 10% SDS-polyacrylamide gels and analyzed by standard Western blotting technique. A rabbit polyclonal antibody to Plk1 was obtained from Upstate Biotechnology (Lake Placid, NY, USA). The filter was also hybridized to a mouse antihuman a-tubulin monoclonal antibody (Amersham Pharmacia Biotech, Uppsala, Sweden), used as a loading control Figure 5 The IR-induced PLK repression is dependent on intact CHEK1 signaling. The MT-1 and HCC1937/BRCA1wt cell lines were treated as previously described. The selective CHEK1 inhibitor UCN-01 (National Cancer Institute, Bethesda, MA, USA) was added in a final concentration of 100 nm to the cell media 15 min before irradiation, and the cells were further incubated in the absence (À) or presence ( þ ) of the IR exposure (8.0 Gy) or UCN-01, or both, as indicated. Expression of PLK mRNA after the indicated time periods was determined by Northern blotting analysis, and 18S rRNA was again used as RNA loading control, as described in the legend to Figure 2 Therapeutics Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute for the gift of UCN-01. This work was supported by the Norwegian Research Council (the 'Metastasis Research Grant').
